Plasmin plays a key role in the regulation of profibrogenic molecules in hepatic stellate cells

Liver International

Volumn 30, Issue 2, 2010, Pages 298-310

  Martínez Rizo, Abril ^a   Bueno Topete, Miriam ^a   González Cuevas, Jaime ^a   Armendáriz Borunda, Juan ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Adenovector; Aprotinin; Fibrogenesis; Hepatic stellate cells; Plasmin; Tranexamic acid; Urokinase plasminogen activator

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMIN; PROTEIN; SKI RELATED NOVEL PROTEIN N; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANEXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; ENZYME ACTIVATION; FIBRIN FORMATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; SUPERNATANT; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; CELL LINE; COLLAGEN TYPE I; FIBRINOLYSIN; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; NERVE TISSUE PROTEINS; RATS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANEXAMIC ACID; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77950623414     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02155.x     Document Type: Article

References (57)

1. Sato S, Higashi T, Ouguchi S, Hino N, Tsuji T. Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma. J Gastroenterol 1994, 29:745-50.
2. Zhang L P, Takahara T, Yata Y. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999, 31:703-11.
3. Bueno M, Salgado S, Beas-Zarate C, Armendariz-Borunda J. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. J Gene Med 2006, 8:1291-9.
4. Gonzalez-Cuevas J, Bueno-Topete MR, Armendariz-Borunda J. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue. J Gastroenterol Hepatol 2006, 21:1544-54.
5. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000, 157:177-87.
6. Bezerra JA, Bugge TH, Melin-Aldana H. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. Proc Natl Acad Sci USA 1999, 96:15143-8.
7. Ng VL, Sabla GE, Melin-Aldana H. Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury. J Hepatol 2001, 35:781-9.
8. Heldin CH, Miyazono K, Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-71.
9. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001, 98:974-9.
10. Massague J. Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev 2003, 17:2993-7.
11. Tan R, Zhang J, Tan X. Downregulation of SnoN expression in obstructive nephropathy is mediated by an enhanced ubiquitin-dependent degradation. J Am Soc Nephrol 2006, 17:2781-91.
12. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. Proc Natl Acad Sci USA 1999, 96:12442-7.
13. Akiyoshi S, Inoue H, Hanai J. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem 1999, 274:35269-77.
14. Fukasawa H, Yamamoto T, Togawa A. Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney Int 2006, 69:1733-40.
15. Yang J, Zhang X, Li Y, Liu Y. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-beta1 signaling. J Am Soc Nephrol 2003, 14:3167-77.
16. Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003, 28:105-12.
17. Herrmann J, Gressner AM, Weiskirchen R. Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function? J Cell Mol Med 2007, 11:704-22.
18. Salgado S, Garcia J, Vera J. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000, 2:545-51.
19. Lieber A, Peeters MJ, Gown A, Perkins J, Kay MA. A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum Gene Ther 1995, 6:1029-37.
20. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997, 3:808-11.
21. Ronday HK, Smits HH, Quax PH. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997, 36:9-15.
22. Tumber A, Papaioannou S, Breckon J. The effects of serine proteinase inhibitors on bone resorption in vitro. J Endocrinol 2003, 178:437-47.
23. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol 1986, 251((Part 1)):G176-80.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-54.
25. Monvoisin A, Neaud V, de Ledinghen V. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 1999, 30:511-8.
26. Kenagy RD, Nikkari ST, Welgus HG, Clowes AW. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Investig 1994, 93:1987-93.
27. Bueno MR, Daneri A, Armendariz-Borunda J. Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J Hepatol 2000, 33:915-25.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-9.
29. Delgado-Rizo V, Salazar A, Panduro A, Armendariz-Borunda J. Treatment with anti-transforming growth factor beta antibodies influences an altered pattern of cytokines gene expression in injured rat liver. Biochim Biophys Acta 1998, 1442:20-7.
30. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991, 19:2499.
31. Yang J, Shultz RW, Mars WM. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Investig 2002, 110:1525-38.
32. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997, 378:151-60.
33. Sancho-Bru P, Bataller R, Gasull X. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. J Hepatol 2005, 43:272-82.
34. Gutierrez-Fernandez A, Parmer RJ, Miles LA. Plasminogen gene expression is regulated by nerve growth factor. J Thromb Haemost 2007, 5:1715-25.
35. Reuning U, Guerrini L, Nishiguchi T. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. Eur J Biochem 1999, 259:143-8.
36. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 2002, 277:20399-408.
37. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004, 61:873-85.
38. Banbula A, Zimmerman TP, Novokhatny VV. Blood inhibitory capacity toward exogenous plasmin. Blood Coagul Fibrinolysis 2007, 18:241-6.
39. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999, 57:1005-32.
40. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995, 9:939-45.
41. Hattori N, Degen JL, Sisson TH. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Investig 2000, 106:1341-50.
42. Kang HM, Kalnoski MH, Frederick M, Chandler WL. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res 2005, 115:327-40.
43. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-39.
44. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003, 28:12-24.
45. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004, 48:411-24.
46. Cabrera S, Gaxiola M, Arreola JL. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int J Biochem Cell Biol 2007, 39:2324-38.
47. Issa R, Zhou X, Constandinou CM. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-808.
48. Preaux AM, D'Ortho MP, Bralet MP, Laperche Y, Mavier P. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 2002, 36:615-22.
49. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-73.
50. Kanno Y, Kuroki A, Okada K. Alpha2-antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis. J Thromb Haemost 2007, 5:2266-73.
51. Cheng Q, Zhao Y, Lawson WE. The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. Blood 2005, 106:3055-7.
52. Zhang G, Kernan KA, Collins SJ. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007, 18:846-59.
53. Krakowski AR, Laboureau J, Mauviel A, Bissell MJ, Luo K. Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proc Natl Acad Sci USA 2005, 102:12437-42.
54. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 1999, 286:771-4.
55. Zhu Q, Krakowski AR, Dunham EE. Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol 2007, 27:324-39.
56. Nagano Y, Mavrakis KJ, Lee KL. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling. J Biol Chem 2007, 282:20492-501.
57. Cai Y, Shen XZ, Zhou CH, Wang JY. Abnormal expression of Smurf2 during the process of rat liver fibrosis. Chin J Dig Dis 2006, 7:237-45.